Role Of Allergen Immunotherapy Research Articles

Role of allergen immunotherapy in the prevention of allergic asthma

The prevalence of allergic asthma is still increasing, which affects the quality of life of patients, threatens their lives, and brings enormous social and economic burden. Allergen immunotherapy (AIT) is the only treatment that can alter the progression of the "Atopic March". It has been widely used in the treatment of allergic rhinitis and conjunctivitis, and its role and effect in the treatment of allergic asthma have been gradually recognized. A few studies have shown that AIT may have a preventive effect on the development and progression of allergic asthma. In this article, the definition of tertiary prevention of allergic asthma is described, and the respective role of AIT in primary, secondary and tertiary prevention of allergic asthma is summarized and analyzed. The aim of this article is to provide evidence for the prevention and control of allergic asthma.

Allergy and Immunotherapy During the Pandemic.

Purpose of ReviewTo summarize and review recent literature on the role of allergen immunotherapy in the setting of a worldwide pandemic.Recent FindingsAt the start of the SARS-CoV-2 pandemic, most elective ambulatory patient care services, including allergen immunotherapy, were suspended. Now with medical practices reopening, allergists must establish plans and protocols for resuming care of allergy patients, including strategies for restarting allergen immunotherapy. While there are no published evidence-based protocols for resuming allergen immunotherapy, limited scientific data and expert opinion suggest that the major factor in dose adjustment is the time elapsed from the last dose.SummaryResuming outpatient allergy services in the setting of the COVID-19 pandemic poses many challenges to the practitioner. Allergy specialists are now faced with developing prudent and evidence-based strategies for safely resuming allergen immunotherapy, while also maintaining a safe environment for staff and patients.

Is AIT the Future of Treating Food Allergies in Children?

This Op-Ed focuses on the usage of allergen immunotherapy (AIT) to treat food allergies in children. It aims to address the safety, efficacy, and areas for improvement within AIT. Food allergies in children represent a growing public health issue with minimal options for treatment. The Op-Ed initially begins the current methods of management and treatment of food allergies, as well as the role of AIT. It also includes current research, as well as progress that has already been made within AIT. Finally, it outlines some of the current flaws of AIT and measures that could be implemented to improve the safety of AIT research.

Role of Allergen Immunotherapy in Asthma Treatment and Asthma Development

Allergen immunotherapy may modify the natural course of allergic diseases and induce remission. It includes subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT). For asthma, allergen immunotherapy using house dust mite (HDM) improves clinical symptoms and airway hyperresponsiveness and decreases drug requirements. Furthermore, it has been suggested that allergen immunotherapy also has the following effects: (1) the effect can be maintained for more than a year even if the treatment is terminated, (2) the remission rate of childhood asthma can be increased, (3) new allergen sensitization can be suppressed, and (4) asthma development can be prevented if allergen immunotherapy was performed in the case of pollinosis. Allergen immunotherapy differs from conventional drug therapy, in particular the effect of modifying the natural course of allergic diseases and the effect of controlling complicated allergic diseases such as rhinoconjunctivitis. The general indication for HDM-SCIT in asthma is HDM-sensitized atopic asthma with mild-to-moderate disease and normal respiratory function. HDM allergens should be involved in the pathogenesis of asthma, and a duration of illness of less than 10 years is desirable. HDM-SLIT is available for allergic rhinitis but not for asthma in Japan. However, as the efficacy of SLIT for asthma has been fully proven internationally, SLIT is also applied in asthmatics with complicated allergic rhinitis in Japan.

Specific allergen immunotherapy for the treatment of allergic asthma: a review of current evidence.

Asthma is frequently associated with atopy, characterized by the production of specific immunoglobulin E in response to environmental allergens. Currently, two types of allergen immunotherapy (AIT) are used in clinical practice: subcutaneous and sublingual immunotherapy, both accepted as key components of the therapeutic repertoire for allergic rhinitis and conjunctivitis. However, their role in asthma remains controversial. The present document is aimed at providing the clinicians with a review of the evidence on the use of AIT in asthma, focusing on the most relevant aspects of its mechanism of action, its efficacy, and existing data on safety, tolerability, and cost-effectivity, both in pediatric and adult populations. A systematic search of MEDLINE, Cochrane, and Clinical Trials databases from 2000 to April of 2016 was carried out by a panel of experts from the Spanish Allergy and Clinical Immunology Scientific Society. Relevant studies prior to the year 2000 included in ulterior systematic reviews were also considered. More than 4000 articles were identified during the search and 241 were selected to retrieve available evidence on AIT, which was graded according to the Oxford classification. All the group members reviewed the resulting text until the final version reached the consensual agreement. A summary of recommendations on the more relevant topics are proposed. The role of AIT as a valuable therapeutic strategy for prevention of exacerbation and progressive decline in lung function is highlighted. Future research should include specific tools for asthma evaluation when assessing AIT effectiveness in asthmatic patients.

Sublingual immunotherapy in the treatment of atopic dermatitis: a systematic review using the GRADE system.

Controversy exists regarding the role of allergen immunotherapy as a therapeutic intervention for patients with atopic dermatitis and aeroallergen sensitivity. Our aim was to critically appraise the evidence supporting the use of sublingual immunotherapy for patients with atopic dermatitis and aeroallergen sensitivity. We performed a literature search using the terms "sublingual immunotherapy" and "atopic dermatitis" and "sublingual immunotherapy" and "eczema." We used the same terms to search PubMed, Ovid, and Scopus. Our limits were "Humans" and "English." We excluded articles that were not in English. These articles were analyzed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. Many studies reported improvement in clinical symptoms of atopic dermatitis. Serious methodological shortcomings were noted including but not limited to lack of control group, lack of randomization, incomplete descriptions of randomization and/or allocation concealment, many enrolled subjects not completing participation, and/or data analysis not by intention to treat.

Inhalant Horse Allergens and Allergies: A Review of the Literature

A wealth of literature exists regarding common allergies to household pets such as cat or dog. Allergy to horse, however, is infrequently discussed in the medical literature despite significant sensitization rates among urban-dwelling subjects without direct exposure to horses. A literature search was conducted in PubMed and additional references were collected from surveying the references of the pulled articles. This review summarizes aspects of IgE-mediated horse allergy including the prevalence and mechanisms for sensitization, clinical presentation, molecular characterization of the major and minor horse allergens, and the role of allergen immunotherapy. There is currently only one horse immunotherapy study showing significant improvement in clinically sensitive patients. The 1997 World Health Organization Position Paper on Immunotherapy lists horse immunotherapy among the areas needing further clinical research. Inclusion of horse into the standard allergen panel for children and adults has been supported by several authors, although further identification and characterization of horse antigens is needed to provide the most efficacious extract. As clinicians, we need to be aware of the potential cross-reactivity among the common mammalian allergens and consider the possibility of known or occult exposure to horse as a possible source of symptom exacerbation in susceptible individuals.

Asthma consultations with specialists: What do the pediatricians seek?

"Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma" includes guidelines for referral to an asthma specialist. Because most cases of asthma are managed by primary care physicians, we intended to explore the referral practices of pediatricians managing childhood asthma. This study was designed to identify important considerations by pediatricians while referring a child to an asthma specialist. An electronic survey was sent to 1200 graduated pediatricians enlisted in the Michigan Chapter, American Academy of Pediatrics directory. The questions explored asthma disease characteristics, physician preferences when referring children with asthma, and reasons and barriers for asthma consultations. All responses were collected anonymously. We received 240/1200 (20%) questionnaires. The majority of pediatricians considered referral to a specialist if a child had severe persistent asthma (201/236 [85.2%]) or had a single life-threatening asthma event (188/229 [82.1%]). The top two likely reasons of referral included poor asthma control (200/224 [89.3%]) and unclear diagnosis (139/224 [62.1%]). We found 74/219 (33.8%) preferred consultation to a pediatric pulmonologist when compared with 93/219 (42.5%) allergists. We found the minority of pediatricians "always" recommended referral to a specialist for the following reasons: allergy skin testing (30/222 [13.5%]), possible allergen immunotherapy (54/223 [24.2%]), and spirometry (26/221 [11.8%]). The major barrier for childhood asthma specialist consultations was issues with medical insurance coverage (137/205 [66.8%]). Allergists have to educate primary care providers about the importance of allergen control, role of allergen immunotherapy, and updating current asthma treatment guidelines when treating a child with allergic asthma.

2 Role of allergen-immunotherapy in asthma(Symposium 7 Immunotherapy, Update and Future)

2 Role of allergen-immunotherapy in asthma(Symposium 7 Immunotherapy, Update and Future)

The Role of Allergen Immunotherapy in Asthma Management

The Role of Allergen Immunotherapy in Asthma Management